MiR-124 exhibits antiproliferative and antiaggressive effects on prostate cancer cells through PACE4 pathway

Prostate

Volumn 74, Issue 11, 2014, Pages 1095-1106

  Kang, Shaosan ^a   Zhao, Yansheng ^a   Hu, Kaimeng ^b   Xu, Chen ^b   Wang, Lei ^a   Liu, Jian ^a   Yao, Anliang ^a   Zhang, Hongmei ^a   Cao, Fenghong ^a  

^a HEBEI UNITED UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

furin; invasiveness; malignancy; tumor progress

Indexed keywords

MICRORNA 124; ONCOPROTEIN; PROTEIN PACE4; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MALE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION;

FURIN; INVASIVENESS; MALIGNANCY; TUMOR PROGRESS;

AGED; AGED, 80 AND OVER; CELL PROLIFERATION; CELLS, CULTURED; FURIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROPROTEIN CONVERTASES; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84903274441     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22822     Document Type: Article

References (52)

1. Couture F, D'Anjou F, Desjardins R, Boudreau F, Day R,. Role of proprotein convertases in prostate cancer progression. Neoplasia 2012; 14 (11): 1032-1042.
2. Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ,. Proprotein convertases: "Master switches" in the regulation of tumor growth and progression. Mol Carcinog 2005; 44 (3): 151-161.
3. Levesque C, Fugère M, Kwiatkowska A, Couture F, Desjardins R, Routhier S, Moussette P, Prahl A, Lammek B, Appel JR, Houghten RA, D'Anjou F, Dory YL, Neugebauer W, Day R,. The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells. J Med Chem 2012; 55 (23): 10501-10511.
4. Fugere M, Day R,. Cutting back on pro-protein convertases: The latest approaches to pharmacological inhibition. Trends Pharmacol Sci 2005; 26 (6): 294- 301.
5. Mbikay M, Sirois F, Yao J, Seidah NG, Chretien M,. Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br J Cancer 1997; 75: 1509-1514.
6. Bassi DE, Lopez De Cicco R, Cenna J, Litwin S, Cukierman E, Klein-Szanto AJ,. PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. Cancer Res 2005; 65: 7310-7319.
7. D'Anjou F, Routhier S, Perreault JP, Latil A, Bonnel D, Fournier I, Salzet M, Day R,. Molecular validation of PACE4 as a target in prostate cancer. Transl Oncol 2011; 4 (3): 157-172.
8. Klee EW, Bondar OP, Goodmanson MK, Dyer RB, Erdogan S, Bergstralh EJ, Bergen HR III, Sebo TJ, Klee G,. Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood. Clin Chem 2012; 58: 599- 609.
9. Couture F, D'Anjou F, Day R,. On the cutting edge of proprotein convertase pharmacology: From molecular concepts to clinical applications. Biomol Concepts 2011; 2 (5): 421- 438.
10. Bai VU, Hwang O, Divine GW, Barrack ER, Menon M, Reddy GP, Hwang C,. Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer. PLoS ONE 2012; 7 (4): e34875.
11. Tian S, Jianhua W,. Comparative study of the binding pockets of mammalian proprotein convertases and its implications for the design of specific small molecule inhibitors. Int J Biol Sci 2010; 6 (1): 89- 95.
12. Fugere M, Limperis PC, Beaulieu Audy V, Gagnon F, Lavigne P, Klarskov K, Leduc R, Day R,. Inhibitory potency and specificity of subtilase-like pro-protein convertase (SPC) prodomains. J Biol Chem 2002; 277 (10): 7648- 7656.
13. Seidah NG, Mayer G, Zaid A, Rousselet E, Nassoury N, Poirier S, Essalmani R, Prat A,. The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol 2008; 40 (6-7): 1111-1125.
14. Maugeri-Saccà M, Coppola V, Bonci D, De Maria R,. MicroRNAs and prostate cancer: From preclinical research to translational oncology. Cancer J 2012; 18 (3): 253-261.
15. Fenderico N, Casamichele A, Profumo V, Zaffaroni N, Gandellini P,. MicroRNA-mediated control of prostate cancer metastasis: Implications for the identification of novel biomarkers and therapeutic targets. Curr Med Chem 2013; 20 (12): 1566-1584.
16. Bartel DP,. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
17. Wang Y, Blelloch R,. Cell cycle regulation by microRNAs in stem cells. Results Probl Cell Differ 2011; 53: 459-472.
18. Osawa S, Shimada Y, Sekine S, Okumura T, Nagata T, Fukuoka J, Tsukada K,. MicroRNA profiling of gastric cancer patients from formalin-fixed paraffin-embedded samples. Oncol Lett 2011; 2 (4): 613-619.
19. Martignani E, Miretti S, Accornero P, Baratta M,. miRNAs highlights in stem and cancer cells. Mini Rev Med Chem 2011; 11 (13): 1165-1182.
20. Tili E, Michaille JJ, Croce CM,. MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol Rev 2013; 253 (1): 167-184.
21. Toh Y, Egashira A, Yamamoto M,. Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma. Gen Thorac Cardiovasc Surg 2013; 61 (5): 262-269.
22. Papagiannakopoulos T, Kosik KS,. MicroRNAs: Regulators of oncogenesis and stemness. BMC Med 2008; 6: 15. doi: 10.1186/1741-7015-6-15
23. Ponomarev ED, Veremeyko T, Weiner HL,. MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS. Glia 2013; 61 (1): 91-103.
24. Patel AR, Jones JS,. Optimal biopsy strategies for the diagnosis and staging of prostate cancer. Curr Opin Urol 2009; 19 (3): 232-237.
25. Mahmoud AM, Zhu T, Parray A, Siddique HR, Yang W, Saleem M, Bosland MC,. Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptor. PLoS ONE 2013; 8 (10): e78479.
26. Uchida K, Chaudhary LR, Sugimura Y, Adkisson HD, Hruska KA,. Proprotein convertases regulate activity of prostate epithelial cell differentiation markers and are modulated in human prostate cancer cells. J Cell Biochem 2003; 88 (2): 394-399.
27. Tian S, Jianhua W,. Comparative study of the binding pockets of mammalian proprotein convertases and its implications for the design of specific small molecule inhibitors. Int J Biol Sci 2010; 6 (1): 89-95.
28. Bassi DE, Mahloogi H, Klein-Szanto AJ,. The proprotein convertases furin and PACE4 play a significant role in tumor progression. Mol Carcinog 2000; 28 (2): 63-69.
29. Lissitzky JC, Luis J, Munzer JS, Benjannet S, Parat F, Chrétien M, Marvaldi J, Seidah NG, Biochem J,. Endoproteolytic processing of integrin pro-alpha subunits involves the redundant function of furin and proprotein convertase (PC) 5A, but not paired basic amino acid converting enzyme (PACE) 4, PC5B or PC7. Biochem J 2000; 346 (1): 133-138.
30. Yuasa K, Suzue K, Nagahama M, Matsuda Y, Tsuji A,. Transcriptional regulation of subtilisin-like proprotein convertase PACE4 by E2F: Possible role of E2F-mediated upregulation of PACE4 in tumor progression. Gene 2007; 402 (1-2): 103-110.
31. Bassi DE, Lopez De Cicco R, Cenna J, Litwin S, Cukierman E, Klein-Szanto AJ,. PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. Cancer Res 2005; 65 (16): 7310-7319.
32. Bassi DE, Zhang J, Cenna J, Litwin S, Cukierman E, Klein-Szanto AJ,. Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis. Neoplasia 2010; 12 (7): 516-526.
33. de Cicco RL, Bassi DE, Benavides F, Conti CJ, Klein-Szanto AJ,. Inhibition of proprotein convertases: Approaches to block squamous carcinoma development and progression. Mol Carcinog 2007; 46 (8): 654-659.
34. Bassi DE, Lopez De Cicco R, Mahloogi H, Zucker S, Thomas G, Klein-Szanto AJ,. Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci U S A 2001; 98 (18): 10326-10331.
35. Byun S, Tortorella MD, Malfait AM, Fok K, Frank EH, Grodzinsky AJ,. Transport and equilibrium uptake of a peptide inhibitor of PACE4 into articular cartilage is dominated by electrostatic interactions. Arch Biochem Biophys 2010; 499: 32-39.
36. Akamatsu T, Azlina A, Purwanti N, Karabasil MR, Hasegawa T, Yao C, Hosoi K,. Inhibition and transcriptional silencing of a subtilisin-like proprotein convertase, PACE4/SPC4, reduces the branching morphogenesis of and AQP5 expression in rat embryonic submandibular gland. Dev Biol 2009; 325 (2): 434-443.
37. Seidah NG, Mayer G, Zaid A, Rousselet E, Nassoury N, Poirier S, Essalmani R, Prat A,. The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol 2008; 40: 1111-1125.
38. Becker GL, Lu Y, Hardes K, Strehlow B, Levesque C, Lindberg I, Sandvig K, Bakowsky U, Day R, Garten W, Steinmetzer T,. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem 2012; 287 (26): 21992-22003.
39. Becker GL, Sielaff F, Than ME, Lindberg I, Routhier S, Day R, Lu Y, Garten W, Steinmetzer T,. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem 2010; 53 (3): 1067-1075.
40. Pizzini S, Bisognin A, Mandruzzato S, Biasiolo M, Facciolli A, Perilli L, Rossi E, Esposito G, Rugge M, Pilati P, Mocellin S, Nitti D, Bortoluzzi S, Zanovello P,. Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics 2013; 14 (1): 589.
41. Srivastava SK, Bhardwaj A, Singh S, Arora S, Wang B, Grizzle WE, Singh AP,. MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis 2011; 32 (12): 1832-1839.
42. Hermeking H,. MicroRNAs in the p53 network: Micromanagement of tumour suppression. Nat Rev Cancer 2012; 12 (9): 613-626.
43. Letonqueze O, Lee J, Vasudevan S,. MicroRNA-mediated posttranscriptional mechanisms of gene expression in proliferating and quiescent cancer cells. RNA Biol 2012; 9 (6): 871-880.
44. Ma X, Becker Buscaglia LE, Barker JR, Li Y,. MicroRNAs in NF-kappaB signaling. J Mol Cell Biol 2011; 3 (3): 159-166.
45. Villadsen SB, Bramsen JB, Ostenfeld MS, Wiklund ED, Fristrup N, Gao S, Hansen TB, Jensen TI, Borre M, Ørntoft TF, Dyrskjøt L, Kjems J,. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer 2012; 106 (2): 366-374.
46. Rajabi H, Ahmad R, Jin C, Joshi MD, Guha M, Alam M, Kharbanda S, Kufe D,. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. Prostate 2012; 72 (15): 1659-1668.
47. Ma S, Chan YP, Kwan PS, Lee TK, Yan M, Tang KH, Ling MT, Vielkind JR, Guan XY, Chan KW,. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Res 2011; 71 (2): 583-592.
48. Ueno K, Hirata H, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, Hinoda Y, Dahiya R,. microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer 2013; 108 (8): 1659-1667.
49. O'Kelly F, Marignol L, Meunier A, Lynch TH, Perry AS, Hollywood D,. MicroRNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol 2012; 9 (7): 397-407.
50. Maugeri-Sacca M, Coppola V, De Maria R, Bonci D,. Functional role of microRNAs in prostate cancer and therapeutic opportunities. Crit Rev Oncog 2013; 18 (4): 303-315.
51. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM,. A. microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006; 103 (7): 2257-2261.
52. Sita-Lumsden A, Dart DA, Waxman J, Bevan CL,. Circulating microRNAs as potential new biomarkers for prostate cancer. Br J Cancer 2013; 108 (10): 1925-1930.